Clinical trials are the experimental foundation on which modern medicine is built. Human medicines cannot be sold without permission from a licensing authority, and permission will not be granted unless a clinical trial has demonstrated the medicine’s success in treating the condition for which it will be marketed. Within this paper, Sarah Iqbal, established business scientist from FirstApp, tries to answer the question: Can mHealth be thought of as the default solution for accelerating completion and increasing success outcomes in clinical trials?